Trade ANI Pharma - ANIP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 69.59 |
| Open | 68.45 |
| 1-Year Change | 4.81% |
| Day's Range | 68.45 - 70.1 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 69.77 | 1.30 | 1.90% | 68.47 | 70.10 | 68.45 |
| Apr 24, 2025 | 69.59 | 1.64 | 2.41% | 67.95 | 69.90 | 67.95 |
| Apr 23, 2025 | 68.33 | -1.02 | -1.47% | 69.35 | 70.18 | 67.76 |
| Apr 22, 2025 | 68.81 | 0.69 | 1.01% | 68.12 | 69.84 | 67.70 |
| Apr 21, 2025 | 67.93 | -0.43 | -0.63% | 68.36 | 69.17 | 67.53 |
| Apr 17, 2025 | 69.16 | 0.21 | 0.30% | 68.95 | 70.35 | 68.95 |
| Apr 16, 2025 | 69.13 | 1.60 | 2.37% | 67.53 | 70.05 | 67.08 |
| Apr 15, 2025 | 69.39 | 1.00 | 1.46% | 68.39 | 69.74 | 67.45 |
| Apr 14, 2025 | 68.61 | 0.16 | 0.23% | 68.45 | 69.28 | 66.66 |
| Apr 11, 2025 | 68.03 | 2.83 | 4.34% | 65.20 | 68.14 | 64.66 |
| Apr 10, 2025 | 65.07 | 0.75 | 1.17% | 64.32 | 65.74 | 62.23 |
| Apr 9, 2025 | 65.84 | 4.36 | 7.09% | 61.48 | 67.29 | 60.97 |
| Apr 8, 2025 | 62.88 | -4.12 | -6.15% | 67.00 | 68.06 | 61.49 |
| Apr 7, 2025 | 66.94 | 2.54 | 3.94% | 64.40 | 68.79 | 64.09 |
| Apr 4, 2025 | 67.39 | 1.17 | 1.77% | 66.22 | 68.03 | 65.59 |
| Apr 3, 2025 | 67.99 | 1.04 | 1.55% | 66.95 | 68.24 | 66.30 |
| Apr 2, 2025 | 69.22 | 3.27 | 4.96% | 65.95 | 69.36 | 65.95 |
| Apr 1, 2025 | 67.90 | 0.98 | 1.46% | 66.92 | 68.73 | 65.45 |
| Mar 31, 2025 | 66.86 | 0.01 | 0.01% | 66.85 | 67.67 | 65.18 |
| Mar 28, 2025 | 67.38 | -0.57 | -0.84% | 67.95 | 68.43 | 67.04 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
ANI Pharma Company profile
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. It operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, ANI Pharmaceuticals Inc revenues increased 4% to $216.1M. Net loss applicable to common stockholders increased 90% to $42.8M. Revenues reflect Royalties from licensing agreements segment increase from $1.4M to $11.8M, Other segment increase from $783K to $1.9M, United States segment increase of 4% to $211.9M. Higher net loss reflects Selling.
Equity composition
6Common Stock $.0001 Par, 3/10, unlim. auth., 93,590,612 issd. Insiders own 2.43%. IPO: N/A. Cl. C Common no Par, 12/10, unlim. auth., 391,286 issd. 5/31/02 1-for-10 reverse stock split. *7/06, private placement of 3,812,978 shares @ 04/06, 1-for-6 Reverese stock split. 07/13, 1-for-6 Reverese stock split.
| Industry: | Pharmaceuticals (NEC) |
210 Main Street West
BAUDETTE
MINNESOTA 56623
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com